Proteomic classification of breast cancer

Current Drug Targets

Volumn 13, Issue 12, 2012, Pages 1495-1509

  Kamel, Dalia ^a   Brady, Bernadette ^a   Tabchy, Adel ^c,d   Mills, Gordon B ^d   Hennessy, Bryan ^a,b,d  

^a OUR LADY OF LOURDES HOSPITAL   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c Breastlink Inc   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Molecular technology; Proteome; RPPA

Indexed keywords

AURORA A KINASE; BETA ACTIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CATHEPSIN V; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE M1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; KI 67 ANTIGEN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN TYROSINE KINASE; RIBOSOME PROTEIN; STROMELYSIN 3; TRANSFERRIN RECEPTOR; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CELL INVASION; CELL PROLIFERATION; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870183727     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530080     Document Type: Article

References (113)

1. Engwegen JY, Gast MC, Beijnen JH, et al. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006; 27(5): 251-259.
2. Caetano-Anollés D, Kim KM, Caetano-Anollés G, et al. Proteome Evolution and the Metabolic Origins of Translation and Cellular Life. J Mol Evol 2011; 72(1): 14-33.
3. Lu M, Whelan SA, Chang HR, et al. Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2- Negative Breast Cancer by Mass Spectrometer. Clin Proteomics 2010; 6(3): 93-103.
4. Solassol J, Marin P, Mangé A, et al. Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers. Bull Cancer 2005; 92(9): 763-768.
5. Espina V, Liotta LA, Petricoin EF. Reverse-phase protein microarrays for theranostics and patient tailored therapy. Methods Mol Biol 2009; 520: 89-105
6. Dupuy L, Gauthier C, Reiter E, et al. A highly sensitive nearinfrared fluorescent detection method to analyze signalling pathways by reverse-phase protein array. Proteomics 2009; 9(24): 5446-5454
7. Brase JC, Mannsperger H, Korf U, et al. Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification. Proteome Sci 2010; 8: 36.
8. Gilabert M, Audebert S, Gonçalves A, et al. Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers. Bull Cancer 2010; 97(3): 321-339.
9. Pietrowska M, Polanska J, Widlak P, et al. Mass spectrometrybased analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer. J Transl Med 2010; 8: 66.
10. Janet L, Moyses S, Loise A. Estrogen receptors and breast cancer. Epidemiologic reviews 1986; 8: 42-59.
11. Sorlie T, Perou M, Børresen-Dale L, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
12. Cheang M, Chia S, Nielsen T, et al. Ki67 Index, HER2 Status, and Prognosis of Patients with Luminal B Breast Cancer. J Natl Cancer Inst 2009; 101(10): 736-750.
13. Hammond EH, Hayes DF, Temin S, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Oncol Pract 2010; 6(4): 195-197.
14. Tamoxifen for early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351 (9114): 1451-1467.
15. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years 'adjuvant treatment for breast cancer. Lancet 2005; 365 (9453): 60-62.
16. Mauri D, Pavlidis N, Ioannidis JP, et al. Survival with aromatize inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006; 98 (18): 1285-1291.
17. Conforti R, Boulet T, Tomasic G, et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: A biomarker study from two randomized trials. Ann Oncol 2007; 18(9): 1477-1483.
18. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295(14): 1658-1667.
19. Miyoshi Y, Murase K, Saito M, et al. Prediction of hormone sensitivity for breast cancers. Breast Cancer 2010; 17(2): 86-91.
20. Hoadley KA, Weigman VJ, Perou CM, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007; 8: 258.
21. Sircoulomb F, Bekhouche I, Chaffanet M, et al. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer 2010; 10: 539.
22. Abd El-Rehim M, Pinder S, Ellis I, et al. Expression and coexpression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004; 91(8): 1532-1542.
23. Pauletti G, Godolphin W, Slamon DJ, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 63-72.
24. Sainsbury JR, Farndon JR, Harris AL, et al. Epidermal-growthfactor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; 1: 1398-1402.
25. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 15: 783-792.
26. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008; 358: 1409-1411.
27. Moulder S. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials. Journal: Clinical Breast Cancer 2010; 10 Suppl 2: S30-S40.
28. Perez EA, Reinholz MM, Hillman DW, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010; 28(28): 4307-4315.
29. Ross JS. Human Epidermal Growth Factor Receptor 2 Testing in 2010: Does Chromosome 17 Centromere Copy Number Make Any Difference? J Clin Oncol 2010; 28(28): 4293-4295.
30. Nagata Y, Lan KH, Yu D, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6(2): 117-127.
31. Crowder RJ, Lombardi DP, Ellis MJ. Successful targeting of ErbB2 receptors-is PTEN the key? Cancer Cell 2004; 6(2): 103-104.
32. Lemoine NR, Barnes DM, Hurst HC, et al. Expression of the ERBB3 gene product in breast cancer. Br J Cancer 1992; 66(6): 1116-1121.
33. Naidu R, Yadav M, Kutty MK, et al. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998; 78(10): 1385-1390.
34. Alimandi M, Romano A, Kraus MH, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995; 10: 1813-1821.
35. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991; 138: 867-873.
36. Trihia H, Murray S, Price K, et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker? Cancer 2003; 97 (5): 1321-1331.
37. Jones RL, Salter J, A'Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; 116(1): 53-68.
38. Dowsett M, Smith IE, Walsh G, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. IMPACT Trialists Group. J Natl Cancer Inst 2007; 99(2): 167-170.
39. Dowsett M, Nielsen TO, Hayes DF, et al. International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103(22): 1656-1664.
40. Olopade OI, Weber BI. Breast cancer genetics. Toward molecular characterization of individuals at increased risk for breast cancer: Part I. PPO Updates: Princ Pract Oncol 1998; 12: 1-12.
41. Grushko TA, Blackwood MA, Olopade OI, et al. Molecular- Cytogenetic Analysis of HER-2/neu Gene in BRCA1-associated Breast Cancers. Cancer Res 2002; 62(5): 1481-1488.
42. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27: 5887-5892.
43. Taneja P, Maglic D, Inoue K, et al. Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clin Med Insights Oncol 2010; 4: 15-34.
44. Pharaoh PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999; 80: 1968-1973.
45. Smith PD, Crossland S, Crook T, et al. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene 1999; 18: 2451-2459.
46. Shin I, Miller T, Arteaga CL. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin Cancer Res 2006; 12(3 Pt 2): 1008s-1112s.
47. Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003; 9(1 Pt 2): 511S-515S.
48. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
49. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005; 97: 1254-1261.
50. Hennessy BT, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
51. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65: 2554-2559.
52. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64: 280-285.
53. Monni O, Barlund M, Mousses S, et al. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci USA 2001; 98: 5711-576.
54. Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010; 223(1): 14-26.
55. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010; 16(14): 3526-3532.
56. Mitra D, Brumlik MJ, Jones FE, et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 2009; 8(8): 2152-2162.
57. Zhang S, Huang WC, Yu D, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011; 17(4): 461-469.
58. Campone M, Bondarenko I, Epstein RJ, et al. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol 2012; 23(3): 610-617.
59. Mayer EL, Baurain JF, Llombart-Cussac A, et al. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 2011; 17(21): 6897-6904.
60. Finn RS, Bengala C, Goldstein LJ, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011; 17(21): 6905-6913.
61. Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004; 9(1): 95-104
62. Yang C, Chen L, Schmidt EV, et al. Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression. Mol Cell Biol 2010; 30(12): 3111-3125.
63. Aaltonen K, Amini RM, Blomqvist C, et al. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat 2009; 113(1): 75-82.
64. Agarwal R, Gonzalez-Angulo AM, Hennessy BT, et al. Integrative analysis of cyclin protein levels identifies cyclin B1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009; 15(11): 3654-3662.
65. Lyman GH, Cosler LE, Hornberger J, et al. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007; 109(6): 1011-1018.
66. Ishibe N, Schully S, Ramsey SD, et al. Use of Oncotype DX in Women with Node-Positive Breast Cancer. PLoS Curr 2011; 3: RRN1249.
67. Lee JJ, Shen J. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers? Am Surg 2011; 77(10): 1364-1367.
68. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 2008; 4(5): 603-610
69. Wulfkuhle JD, Edmiston KH, Petricoin EF 3rd, et al. Technology insight: pharmacoproteomics for cancer--promises of patienttailored medicine using protein microarrays. Nat Clin Pract Oncol 2006; 3(5): 256-268.
70. Medintz IL, Uyeda HT, Mattoussi H, et al. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005; 4(6): 435-446.
71. Tada H, Higuchi H, Ohuchi N, et al. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res 2007; 67(3): 1138-1144.
72. Press MF, Slamon DJ, Bernstein L, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20(14): 3095-3105.
73. Leader M, Patel J, Henry K, et al. An analysis of the sensitivity and specificity of the cytokeratin marker CAM 5.2 for epithelial tumours. Results of a study of 203 sarcomas, 50 carcinomas and 28 malignant melanomas. Histopathology 1986; 10(12): 1315-1324.
74. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981-1989.
75. Diamandis EP, van der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 2005; 11(3): 963-965.
76. Gross JH. Liquid injection field desorption/ionization-mass spectrometry of ionic liquids. J Am Soc Mass Spectrom 2007; 18(12): 2254-2262.
77. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422:198-207.
78. Petricoin EF III, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-575.
79. Stoeckli M, Chaurand P, Caprioli RM, et al. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001; 7(4): 493-496.
80. Seeley EH, Caprioli RM. Molecular imaging of proteins in tissues by mass spectrometry. Proc Natl Acad Sci USA 2008; 105(47): 18126-18131.
81. Aerni HR, Cornett DS, Caprioli RM. High-throughput profiling of formalin-fixed paraffin-embedded tissue using parallel electrophoresis and matrix-assisted laser desorption ionization mass spectrometry. Anal Chem 2009; 81(17): 7490-7495.
82. Schwamborn K, Caprioli RM. MALDI imaging mass spectrometry-- painting molecular pictures. Mol Oncol 2010; 4(6): 529-538.
83. Bauer JA, Chakravarthy AB, Pietenpol JA, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 2010; 16(2): 681-690.
84. Girish S, Gupta M, Joshi A, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012; 69(5): 1229-1240.
85. Zhang K, Yuan K, Fu R, et al. Identification of Potential Markers Related to Neoadjuvant Chemotherapy Sensitivity of Breast Cancer by SELDI-TOF MS. Appl Biochem Biotechnol 2012; 166(3): 753-763.
86. Yang WS, Moon HG, Lee C, et al. Proteomic Approach Reveals FKBP4 and S100A9 as Potential Prediction Markers of Therapeutic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. J Proteome Res 2012; 11(2): 1078-1088.
87. Andersson M, Andren P, Caprioli RM. MALDI Imaging and Profiling Mass Spectrometry in Neuroproteomics. Neuroproteomics. Alzate O, editor. Boca Raton (FL): 2010: Chapter 7.
88. De Wildt RM, Mundy CR, Tomlinson IM, et al. Antibody arrays for high-throughput screening of antibody-antigen interactions. Nat Biotechnol 2000; 18(9): 989-994.
89. Cahill DJ. Protein and antibody arrays and their medical applications. J Immunol Methods 2001; 250(1/2): 81-91.
90. Vazquez-Martin A, Colomer R, Menendez JA. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer 2007; 43(7): 1117-1124.
91. Sheehan KM, Calvert VS, Wulfkuhle JD, et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005; 4(4): 346-355.
92. Espina V, Mehta AI, Liotta LA, et al. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 2003; 3(11): 2091-100.
93. Hennessy BT, Lu Y, Bedrosian I, et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 2010; 6(4): 129-151.
94. Wulfkuhle JD, Speer R, Pierobon M, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008; 7: 1508-1517.
95. Petricoin EF 3rd, Bichsel VE, Calvert VS, et al. Mapping molecular networks using proteomics: a vision for patienttailored combination therapy. J Clin Oncol 2005; 23: 3614-3621.
96. Ibarra-Drendall C, Troch MM, Seewaldt VL, et al. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of prosurvival pathways. Breast Cancer Res Treat 2012; 132(2): 487-498.
97. Rapkiewicz A, Espina V, Abati A, et al. The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer 2007; 111(3): 173-284.
98. Mueller C, Edmiston KH, Espina V, et al. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 2011; 6(8): e23780.
99. Espina V, Mueller C, Liotta LA. Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology. Methods Mol Biol 2011; 785: 23-43.
100. Espina V, Edmiston KH, Pastore L, et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008; 7(10): 1998-2018.
101. Grubb RL, Deng J, Pinto PA, et al. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res 2009; 8: 3044-3054.
102. Sheehan KM, Gulmann C, Eichler GS, et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveal epithelial-mesenchymal transition. Oncogene 2008; 27: 323-331.
103. Ornstein DK, Gillespie JW, Paweletz CP, et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis. 2000; 21: 2235-2242.
104. Emmert-Buck MR, Gillespie JW, Paweletz CP, et al. An approach to proteomic analysis of human tumors. Mol Carcinog 2000; 27: 158-165.
105. Dillon RL, Marcotte R, Muller WJ, et al. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res 2009; 69(12): 5057-5064.
106. Boyd ZS, Wu QJ, Lackner MR, et al. Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol Cancer Ther 2008; 7(12): 3695-3706.
107. Gonzalez-Angulo AM, Hennessy BT, Mills GB, et al. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 2011; 8(1): 11.
108. Stemke-Hale K, Gonzalez-Angulo AM, Hennessy BT, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. Cancer Res 2008; 68(15): 6084-6091.
109. Tibes R, Qiu Y, Kornblau S, et al. Reverse phase protein array (RPPA) Validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006; 5(10): 2512-2521.
110. Liang J, Shao SH, Mills GB, et al. The energy sensing LKB1- AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9: 218-224.
111. Hu J, He X, Mills GB, et al. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007; 23: 1986-1994.
112. Hennessy BT, Lu Y, Hall H, et al. Quantified pathway inhibition as a pharmacodynamic marker facilitating optimal targeted therapy dosing: Proof of principle with the AKT inhibitor perifosine. Clin Cancer Res 2007; 13: 7421-7431.
113. Liotta LA, Espina V, Petricoin EF 3 rd, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003; (4): 317-325.